THE SCIENCE AND TECHNOLOGY TO TRANSLATE ATMPs FROM LAB TO CLINIC
CAMP is a Vinnova funded project focussing on the science and technology required to translate ATMPs from lab to clinic, including bioprocess development, GMP production and logistics. CAMP drives collaboration between researchers, GMP competent resources, industry and hospitals. CAMP gathers all of the university hospitals in Sweden, all research institutes with significant activity in ATMP and both large and small companies active in the ATMP field.
Coordinator: Umeå universitet
Partners: ACOUSORT, Akademiska Sjukhuset, Amniotics, AstraZeneca, Celgene (a BMS company), Cellastra Inc., CELLINK, CELLSEED, Cytiva, Göteborgs Universitet, Idogen, IsletOne, Karolinska Institutet, Karolinska Universitetssjukhuset, Key2Compliance, KTH, Linköping University, LIF, MAGic Bioprocessing, MEDICON VILLAGE, MitoSense, NEOGAP Therapeutics, NextCell Pharma, NORICON, NorthX Biologics, Novartis, PFIZER, Region Örebro, Region Skåne, Region Västerbotten, Region Östergötland, RISE, Svenska Vaccinfabriken Produktion, TAKARA BIO EUROPE, TATAA Biocenter, Uppsala University Hospital, Uppsala universitet, VÄSTRA GÖTALANDSREGION, VERIGRAFT, VivaBioCell S.p.A., Xintela, XNK Therapeutics, YSDS
- Process Development
- Infrastructure for GMP manufacturing
- Quality control, shelf-life and logistics
For a list of projects see here
Contact: Jukka Lausmaa – Centre Director
The overall long term objective is to develop general cell processing development principles and methods for an effective transfer from preclinical to clinical, GMP-compatible production.